

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P O Box 1450 Alexandria, Virginsa 22313-1450 www.msplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/319,156	11/02/1999	GLAUCIA PARANHOS-BACCALA	103514	2490
25944 OLIFF & BER	7590 05/13/200 PRIDGE PLC	EXAMINER		
P.O. BOX 320	850	PARKIN, JEFFREY S		
ALEXANDRIA, VA 22320-4850			ART UNIT	PAPER NUMBER
			1648	
			MAIL DATE	DELIVERY MODE
			05/13/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 09/319 156 PARANHOS-BACCALA ET AL. Office Action Summary Examiner Art Unit Jeffrey S. Parkin 1648 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 03 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 29 September 2008. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1.7.9.14.15.26.60-64 and 66 is/are pending in the application. 4a) Of the above claim(s) 26 is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 1,7,9,14,15,60-64 and 66 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) ____ __ are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on 07 November 2005 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abevance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner, Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☒ None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date. Notice of Draftsperson's Patent Drawing Review (PTO-948)

Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date ______.

5) Notice of Informal Patent Application

6) Other:

Detailed Office Action

Status of the Claims

As set forth in the advisory action dated 11 December, 2008, the finality of the final rejection dated 27 March, 2008, has been withdrawn. The amendment-after-final filed 29 September, 2008, has been entered. Claims 1, 7, 9, 14, 15, 26, 60-64, and 66 are pending in the instant application. Claim 26 stands withdrawn from further consideration by the examiner, pursuant to 37 C.F.R. § 1.142(b), as being drawn to a non-elected invention (see the restriction requirement mailed 16 February, 2001).

35 U.S.C. § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. \S 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

The previous rejection of claims 1, 7, 14, 15, and 60-64 under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, is hereby withdrawn in response to applicants' amendment.

35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. \S 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Written Description

The previous rejection of claims 1, 7, 9, 14, 15, and 60-64 under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, is hereby withdrawn in view of applicants' amendment.

35 U.S.C. § 102(b)

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The previous rejection of claims 1, 7, 14, 15, and 60 under 35 U.S.C. § 102(b) as being clearly anticipated by Boehringer Mannheim (1994), is hereby withdrawn in response to applicants' amendment.

35 U.S.C. § 119

Acknowledgment is hereby made of applicants' claim for foreign priority based on FR 97/08816 filed 07 July, 1997. It is noted, however, that applicants have **NOT** filed a certified copy **AND** English translation of this application as required by 35 U.S.C. § 119(b). Accordingly, the foreign priority claim has **NOT** been entered.

35 U.S.C. § 102(e)

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1, 7, 9, 14, 15, 60, 61, 63, and 66 are rejected under 35 U.S.C. § 102(e) as being clearly anticipated by Perron *et al.* (2003, U.S. Patent No. 6,582,703 B2). Perron and associates provide isolated polynucleotides that are identical to SEQ ID NOS. 6, 9, 10, and 12 (see SEQ ID NOS.: 102, 105, 106, and 108,

-4-

^{1.} The earliest effective filing date of U.S. Patent No. 6,582,703 B2 is 26 November, 1997.

respectively). Thus, this teaching meets all of the claimed limitations.

35 U.S.C. § 103(a)

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 62 and 64 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Perron et al. (2003, U.S. Patent No. 6,582,703 B2). Claim 62 is directed toward isolated genomic DNA comprising SEQ ID NOS. 6, 9, or 12 and claim 64 is directed toward an expression vector comprising the claimed SEQ ID NOS. As set forth supra, Perron and associates provide isolated polynucleotides that are identical to SEQ ID NOS. 6, 9, and 12 (see SEQ ID NOS.: 102, 105, and 108, respectively). This teaching does not disclose isolated genomic DNA comprising these sequences or expression vectors comprising said sequences. However, it would have been prima facie obvious to one of ordinary skill in the art at the time of the invention to isolate the claimed retroviral sequences from a number of sources (e.g., genomic DNA comprising proviral copies of the retrovirus) to facilitate further genotypic/phenotypic

characterization of the virus. One of ordinary skill in the art would have also been motivated to place the claimed sequences in an expression vector to encode the corresponding protein. The protein would obviously be useful for the generation of a number of immunological, biochemical and diagnostic reagents.

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Larry R. Helms, can be reached at (571) 272-0832. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on

access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

/Jeffrey S. Parkin/

Jeffrey S. Parkin, Ph.D. Primary Examiner, Art Unit 1648

10 May, 2009

Appendix A: Sequence Search Results for U.S. Serial No. 09/319.156

SEO ID NO.: 6 RESULT 1 US-08-979-847B-102 ; Sequence 102, Application US/08979847B ; Patent No. 6582703 GENERAL INFORMATION: APPLICANT: PERRON, HERVE BESEME, FREDERIC BEDIN, FREDERIC PARANHOS-BACCALA, GLAUCIA KOMURIAN-PRADEL, FLORENCE JOLIVET-REYNAUD, COLETTE MANDRAND, BERNARD GARSON, JEREMY TUKE, PHILIP TITLE OF INVENTION: VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC PURPOSES NUMBER OF SEQUENCES: 210 CORRESPONDENCE ADDRESS: ADDRESSEE: OLIFF & BERRIDGE, PLC STREET: P.O. BOX 19928 ; CITY: ALEXANDRIA STATE: VA COUNTRY: USA ZIP: 22320 COMPUTER READABLE FORM: ; MEDIUM TYPE: Floppy disk COMPUTER: IBM PC compatible OPERATING SYSTEM: PC-DOS/MS-DOS SOFTWARE: PatentIn Release #1.0, Version #1.30 CURRENT APPLICATION DATA: APPLICATION NUMBER: US/08/979,847B FILING DATE: 26-No. 6582703-1997 CLASSIFICATION: ATTORNEY/AGENT INFORMATION: NAME: BERRIDGE, WILLIAM P. REGISTRATION NUMBER: 30,024 REFERENCE/DOCKET NUMBER: WPB 39046A ; TELECOMMUNICATION INFORMATION:

TELEPHONE: 703-836-6400 TELEFAX: 703-836-2787

INFORMATION FOR SEQ ID NO: 102: SEQUENCE CHARACTERISTICS:

```
LENGTH: 635 base pairs
                TYPE: nucleic acid
                STRANDEDNESS: single
                TOPOLOGY: linear
          MOLECULE TYPE: cDNA
          SEQUENCE DESCRIPTION: SEO ID NO: 102:
US-08-979-847B-102
  Ouerv Match
                              100.0%; Score 635; DB 4; Length 635;
  Best Local Similarity 100.0%; Pred. No. 2e-203;
  Matches 635: Conservative
                                     0; Mismatches
                                                            0:
                                                                Indels
         0:
Gaps
Qv
           1 CCCTGTATCTTTAACCTCCTTGTTAAGTTTGTCTCTTCCAGAATCAAAACTGTAAAACTA 60
Db
           1 CCCTGTATCTTTAACCTCCTTGTTAAGTTTGTCTCTTCCAGAATCAAAACTGTAAAACTA 60
          61 CAAATTGTTCTTCAAATGGAGCACCAGATGGAGTCCATGACTAAGATCCACCGTGGACCC 120
          61 CAAATTGTTCTTCAAATGGAGCACCAGATGGAGTCCATGACTAAGATCCACCGTGGACCC 120
Dh
         121 CTGGACCGCCTGCTAGCCCATGCTCCGATGTTAATGACATTGAAGGCACCCCTCCCGAG 180
Db
         121 CTGGACCGCCTGCTAGCCCATGCTCCGATGTTAATGACATTGAAGGCACCCCTCCCGAG 180
         181 GAAATCTCAACTGCACAACCCCTACTATGCCCCAATTCAGCGGGAAGCAGTTAGAGCGGT 240
         181 GAAATCTCAACTGCACAACCCCTACTATGCCCCAATTCAGCGGGAAGCAGTTAGAGCGGT 240
Db
         241 CATCAGCCAACCTCCCCAACAGCACTTGGGTTTTCCTGTTGAGAGGGGGGGACTGAGAGAC 300
         241 CATCAGCCAACCTCCCCAACAGCACTTGGGTTTTCCTGTTGAGAGGGGGGGACTGAGAGAC 300
Dh
         301 AGGACTAGCTGGATTTCCTAGGCCAACGAAGAATCCCTAAGCCTAGCTGGGAAGGTGACT 360
         301 AGGACTAGCTGGATTTCCTAGGCCAACGAAGAATCCCTAAGCCTAGCTGGGAAGGTGACT 360
         361 GCATCCACCTCTAAACATGGGGCTTGCAACTTAGCTCACACCCGACCAATCAGAGAGCTC 420
Db
         361 GCATCCACCTCTAAACATGGGGCTTGCAACTTAGCTCACACCCGACCAATCAGAGAGCTC 420
         421 ACTABARTGCTARTTAGGCARARATAGGAGGTARAGARATAGCCRATCATCTATTGCCTG 480
         421 ACTAAAATGCTAATTAGGCAAAAATAGGAGGTAAAGAAATAGCCAATCATCTATTGCCTG 480
         481 AGAGCACAGCGGGAGGGACAAGGATCGGGATATAAACCCAGGCATTCGAGCCGGCAACGG 540
         481 AGAGCACAGCGGGAGGGACAAGGATCGGGATATAAACCCAGGCATTCGAGCCGGCAACGG 540
Dh
         541 CAACCCCTTTGGGTCCCCTCCTTTGTATGGGCGCTCTGTTTTCACTCTATTTCACTCT 600
QУ
Db
         541 CAACCCCTTTGGGTCCCCTCCCTTTGTATGGGCGCTCTGTTTTCACTCTATTTCACTCT 600
Qy
         601 ATTAAATCTTGCAACTGAAAAAAAAAAAAAAAAAA 635
Db
         601 ATTAAATCTTGCAACTGAAAAAAAAAAAAAAAAAAA 635
```

SEQ ID NO.: 9

```
US-08-979-847B-105
; Sequence 105, Application US/08979847B
; Patent No. 6582703
: GENERAL INFORMATION:
    APPLICANT: PERRON, HERVE
                   BESEME, FREDERIC
                    BEDIN, FREDERIC
                    PARANHOS-BACCALA, GLAUCIA
                   KOMURIAN-PRADEL, FLORENCE
                   JOLIVET-REYNAUD, COLETTE
                   MANDRAND, BERNARD
                    GARSON, JEREMY
                    TUKE, PHILIP
        TITLE OF INVENTION: VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS
                             ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR
DIAGNOSTIC, PROPHYLACTIC AND
                            THERAPEUTIC PURPOSES
        NUMBER OF SEQUENCES: 210
         CORRESPONDENCE ADDRESS:
              ADDRESSEE: OLIFF & BERRIDGE, PLC
              STREET: P.O. BOX 19928
             CITY: ALEXANDRIA
              STATE: VA
              COUNTRY: USA
              ZIP: 22320
       COMPUTER READABLE FORM:
              MEDIUM TYPE: Floppy disk
              COMPUTER: IBM PC compatible
              OPERATING SYSTEM: PC-DOS/MS-DOS
              SOFTWARE: PatentIn Release #1.0, Version #1.30
       CURRENT APPLICATION DATA:
              APPLICATION NUMBER: US/08/979,847B
              FILING DATE: 26-No. 6582703-1997
              CLASSIFICATION:
       ATTORNEY/AGENT INFORMATION:
              NAME: BERRIDGE, WILLIAM P.
              REGISTRATION NUMBER: 30,024
              REFERENCE/DOCKET NUMBER: WPB 39046A
       TELECOMMUNICATION INFORMATION:
              TELEPHONE: 703-836-6400
              TELEFAX: 703-836-2787
; INFORMATION FOR SEO ID NO: 105:
        SEQUENCE CHARACTERISTICS:
              LENGTH: 1481 base pairs
             TYPE: nucleic acid
              STRANDEDNESS: single
```

```
TOPOLOGY: linear
          MOLECULE TYPE: cDNA
          SEQUENCE DESCRIPTION: SEO ID NO: 105:
US-08-979-847B-105
  Query Match
                              100.0%; Score 1481; DB 4; Length 1481;
  Best Local Similarity 100.0%; Pred. No. 0;
  Matches 1481; Conservative 0; Mismatches
                                                            0; Indels
                                                                             0:
Gaps
        0;
           1 ATGGCCCTCCCTTATCATACTTTTCTCTTTACTGTTCTCTTACCCCCTTTCGCTCTCACT 60
           1 ATGGCCCTCCCTTATCATACTTTTCTCTTTACTGTTCTCTTACCCCCTTTCGCTCTCACT 60
Db
          61 GCACCCCTCCATGCTGCTGCTACAACCAGTAGCTCCCCTTACCAAGAGTTTCTATGAAGA 120
QУ
Db
          61 GCACCCCCTCCATGCTGCTGCTACAACCAGTAGCTCCCCTTACCAAGAGTTTCTATGAAGA 120
         121 ACGCGGCTTCCTGGAAATATTGATGCCCCATCATATAGGAGTTTATCTAAGGGAAACTCC 180
QУ
Dh
         121 ACGCGGCTTCCTGGAAATATTGATGCCCCATCATATAGGAGTTTATCTAAGGGAAACTCC 180
QУ
         181 ACCTTCACTGCCCACACCCATATGCCCCGCAACTGCTATAACTCTGCCACTCTTTGCATG 240
Dh
         181 ACCTTCACTGCCCACACCCATATGCCCCGCAACTGCTATAACTCTGCCACTCTTTGCATG 240
         241 CATGCAAATACTCATTATTGGACAGGGAAAATGATTAATCCTAGTTGTCCTGGAGGACTT 300
         241 CATGCAAATACTCATTATTGGACAGGGAAAATGATTAATCCTAGTTGTCCTGGAGGACTT 300
Db
Qy
         301 GGAGCCACTGTCTGTTGGACTTACTTCACCCATACCAGTATGTCTGATGGGGGTGGAATT 360
Db
         301 GGAGCCACTGTCTGTTGGACTTACTTCACCCATACCAGTATGTCTGATGGGGGTGGAATT 360
         361 CAAGGTCAGGCAAGAGAAAACAAGTAAAGGAAGCAATCTCCCAACTGACCCGGGGACAT 420
Db
         361 CAAGGTCAGGCAAGAGAAAAACAAGTAAAGGAAGCAATCTCCCAACTGACCCGGGGACAT 420
         421 AGCACCCCTAGCCCCTACAAAGGACTAGTTCTCTCAAAACTACATGAAACCCTCCGTACC 480
         421 AGCACCCCTAGCCCCTACAAAGGACTAGTTCTCTCAAAACTACATGAAACCCTCCGTACC 480
Db
         481 CATACTCGCCTGGTGAGCCTATTTAATACCACCCTCACTCGGCTCCATGAGGTCTCAGCC 540
Db
         481 CATACTCGCCTGGTGAGCCTATTTAATACCACCCTCACTCGGCTCCATGAGGTCTCAGCC 540
         541 CAAAACCCTACTAACTGTTGGATGTGCCTCCCCTGCACTTCAGGCCATACATTTCAATC 600
QУ
Dh
         541 CAAAACCCTACTAACTGTTGGATGTGCCTCCCCCTGCACTTCAGGCCATACATTTCAATC 600
         601 CCTGTTCCTGAACAATGGAACAACTTCAGCACAGAAATAAACACCACTTCCGTTTTAGTA 660
Dh
         601 CCTGTTCCTGAACAATGGAACAACTTCAGCACAGAAATAAACACCACTTCCGTTTTAGTA 660
Qv
         661 GGACCTCTTGTTTCCAATCTGGAAATAACCCATACCTCAAACCTCACCTGTGTAAAATTT 720
Db
         661 GGACCTCTTGTTTCCAATCTGGAAATAACCCATACCTCAAACCTCACCTGTGTAAAATTT 720
```

Qy	721	AGCAATACTATAGACACAACCAGCTCCCAATGCATCAGGTGGGTAACACCTCCCACACGA	780
Db	721	AGCAATACTATAGACACAACCAGCTCCCAATGCATCAGGTGGGTAACACCTCCCACACGA	780
Qy	781	ATAGTCTGCCTACCCTCAGGAATATTTTTTGTCTGTGGTACCTCAGCCTATCATTGTTTG	840
Db	781	${\tt ATAGTCTGCCTACCCTCAGGAATATTTTTTGTCTGTGGTACCTCAGCCTATCATTGTTTG}$	840
QУ	841	AATGGCTCTTCAGAATCTATGTGCTTCCTCTCATTCTTAGTGCCCCCTATGACCATCTAC	900
Db	841	${\tt AATGGCTCTTCAGAATCTATGTGCTTCCTCATTCTTAGTGCCCCCTATGACCATCTAC}$	900
Qy	901	ACTGAACAAGATTTATACAATCATGTCGTACCTAAGCCCCACAACAAAAGAGTACCCATT	960
Db	901	${\tt ACTGAACAAGATTTATACAATCATGTCGTACCTAAGCCCCACAACAAAAGAGTACCCATT}$	960
QУ	961	CTTCCTTTTGTTATCAGAGCAGGAGTGCTAGGCAGCTAGGCACTAGCATTGGCAGTATC	1020
Db	961	$\tt CTTCCTTTTGTTATCAGAGCAGGAGTGCTAGGCAGGACTAGGTACTGGCATTGGCAGTATC$	1020
QУ	1021	ACAACCTCTACTCAGTTCTACTACAAACTATCTCAAGAAATAAAT	1080
Db	1021	ACAACCTCTACTCAGTTCTACTACAAACTATCTCAAGAAATAAAT	1080
Qy	1081	GTCACTGACTCCCTGGTCACCTTGCAAGATCAACTTAACTCCCTAGCAGCAGTAGTCCTT	1140
Db	1081	$\tt GTCACTGACTCCCTGGTCACCTTGCAAGATCAACTTAACTCCCTAGCAGCAGTAGTCCTT$	1140
QУ	1141	CAAAATCGAAGAGCTTTAGACTTGCTAACCGCCAAAAGAGGGGGAACCTGTTTATTTTTA	1200
Db	1141	CAAAATCGAAGAGCTTTAGACTTGCTAACCGCCAAAAGAGGGGGAACCTGTTTATTTTTA	1200
QУ	1201	GGAGAAGAACGCTGTTATTATGTTAATCAATCCAGAATTGTCACTGAGAAAGTTAAAGAA	1260
Db	1201	GGAGAAGAACGCTGTTATTATGTTAATCAATCCAGAATTGTCACTGAGAAAGTTAAAGAA	1260
QУ	1261	ATTCGAGATCGAATACAATGTAGAGCAGAGGAGCTTCAAAACACCGAACGCTGGGGCCTC	1320
Db	1261	$\tt ATTCGAGATCGAATACAATGTAGAGCAGAGGAGCTTCAAAACACCGAACGCTGGGGCCTC$	1320
QУ	1321	CTCAGCCAATGGATGCCCTGGGTTCTCCCCTTCTTAGGACCTCTAGCAGCTCTAATATTG	1380
Db	1321	CTCAGCCAATGGATGCCCTGGGTTCTCCCCTTCTTAGGACCTCTAGCAGCTCTAATATTG	1380
Qy	1381	TTACTCCTCTTTGGACCCTGTATCTTTAACCTCCTTGTTAAGTTTGTCTCTCCAGAATT	1440
Db	1381	${\tt TTACTCCTCTTTGGACCCTGTTATCTTTAACCTCCTTGTTAAGTTTGTCTCTTCCAGAATT}$	1440
Qy	1441	GAAGCTGTAAAGCTACAGATGGTCTTACAAATGGAACCCCA 1481	
Db	1441	GAAGCTGTAAAGCTACAGATGGTCTTACAAATGGAACCCCA 1481	

SEQ ID NO.: 10

```
RESULT 1
US-08-979-847B-106
; Sequence 106, Application US/08979847B
; Patent No. 6582703
: GENERAL INFORMATION:
    APPLICANT: PERRON, HERVE
                   BESEME, FREDERIC
                    BEDIN, FREDERIC
                    PARANHOS-BACCALA, GLAUCIA
                   KOMURIAN-PRADEL, FLORENCE
                   JOLIVET-REYNAUD, COLETTE
                   MANDRAND, BERNARD
                    GARSON, JEREMY
                    TUKE, PHILIP
        TITLE OF INVENTION: VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS
                             ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR
DIAGNOSTIC, PROPHYLACTIC AND
                            THERAPEUTIC PURPOSES
        NUMBER OF SEQUENCES: 210
         CORRESPONDENCE ADDRESS:
              ADDRESSEE: OLIFF & BERRIDGE, PLC
              STREET: P.O. BOX 19928
             CITY: ALEXANDRIA
              STATE: VA
              COUNTRY: USA
              ZIP: 22320
       COMPUTER READABLE FORM:
              MEDIUM TYPE: Floppy disk
              COMPUTER: IBM PC compatible
              OPERATING SYSTEM: PC-DOS/MS-DOS
              SOFTWARE: PatentIn Release #1.0, Version #1.30
       CURRENT APPLICATION DATA:
              APPLICATION NUMBER: US/08/979,847B
              FILING DATE: 26-No. 6582703-1997
              CLASSIFICATION:
       ATTORNEY/AGENT INFORMATION:
              NAME: BERRIDGE, WILLIAM P.
              REGISTRATION NUMBER: 30,024
              REFERENCE/DOCKET NUMBER: WPB 39046A
       TELECOMMUNICATION INFORMATION:
              TELEPHONE: 703-836-6400
              TELEFAX: 703-836-2787
; INFORMATION FOR SEO ID NO: 106:
       SEQUENCE CHARACTERISTICS:
              LENGTH: 493 amino acids
             TYPE: amino acid
              STRANDEDNESS: single
```

```
TOPOLOGY: linear
          MOLECULE TYPE: peptide
          SEQUENCE DESCRIPTION: SEO ID NO: 106:
US-08-979-847B-106
  Query Match
                              99.9%; Score 2632; DB 4; Length 493;
  Best Local Similarity 100.0%; Pred. No. 2.8e-262;
  Matches 493; Conservative 0; Mismatches 0; Indels
                                                                          0:
Gaps
           1 MALPYHTFLFTVLLPPFALTAPPPCCCTTSSSPYOEFLXRTRLPGNIDAPSYRSLSKGNS 60
Qу
           1 MALPYHTFLFTVLLPPFALTAPPPCCCTTSSSPYQEFLXRTRLPGNIDAPSYRSLSKGNS 60
Dh
          61 TFTAHTHMPRICYNSATLCMHANTHYWTGKMINPSCPGGLGATVCWTYFTHTSMSDGGGI 120
Dh
          61 TFTAHTHMPRNCYNSATLCMHANTHYWTGKMINPSCPGGLGATVCWTYFTHTSMSDGGGI 120
         121 QGQAREKQVKEAISQLTRGHSTPSPYKGLVLSKLHETLRTHTRLVSLFNTTLTRLHEVSA 180
Qу
         121 OGOAREKOVKEAISOLTRGHSTPSPYKGLVLSKLHETLRTHTRLVSLFNTTLTRLHEVSA 180
Qy
         181 QNPTNCWMCLPLHFRPYISIPVPEQWNNFSTEINTTSVLVGPLVSNLEITHTSNLTCVKF 240
         181 QNPTNCWMCLPLHFRPYISIPVPEQWNNFSTEINTTSVLVGPLVSNLEITHTSNLTCVKF 240
Db
         241 SNTIDTTSSQCIRWVTPPTRIVCLPSGIFFVCGTSAYHCLNGSSESMCFLSFLVPPMTIY 300
Qν
Db
         241 SNTIDTTSSOCIRWYTPPTRIVCLPSGIFFVCGTSAYHCLNGSSESMCFLSFLVPPMTIY 300
         301 TEODLYNHVVPKPHNKRVPILPFVIRAGVLGRLGTGIGSITTSTOFYYKLSOEINGDMEO 360
         301 TEQDLYNHVVPKPHNKRVPILPFVIRAGVLGRLGTGIGSITTSTQFYYKLSQEINGDMEQ 360
Dh
Qу
         361 VTDSLVTLODOLNSLAAVVLONRRALDLLTAKRGGTCLFLGEERCYYVNOSRIVTEKVKE 420
         361 VTDSLVTLQDQLNSLAAVVLQNRRALDLLTAKRGGTCLFLGEERCYYVNQSRIVTEKVKE 420
         421 IRDRIQCRAEELQNTERWGLLSQWMPWVLPFLGPLAALILLLLFGPCIFNLLVKFVSSRI 480
Dh
         421 IRDRIOCRAEELONTERWGLLSOWMPWVLPFLGPLAALILLLLFGPCIFNLLVKFVSSRI 480
Qy
         481 EAVKLQMVLQMEP 493
Dh
         481 EAVKLOMVLOMEP 493
```

SEQ ID NO.: 12

```
RESHLT 1
US-08-979-847B-108
; Sequence 108, Application US/08979847B
; Patent No. 6582703
: GENERAL INFORMATION:
    APPLICANT: PERRON, HERVE
                   BESEME, FREDERIC
                   BEDIN, FREDERIC
                   PARANHOS-BACCALA, GLAUCIA
                   KOMURIAN-PRADEL, FLORENCE
                   JOLIVET-REYNAUD, COLETTE
                   MANDRAND, BERNARD
                   GARSON, JEREMY
                   TUKE, PHILIP
       TITLE OF INVENTION: VIRAL MATERIAL AND NUCLEOTIDE FRAGMENTS
                            ASSOCIATED WITH MULTIPLE SCLEROSIS, FOR
DIAGNOSTIC, PROPHYLACTIC AND
                            THERAPEUTIC PURPOSES
        NUMBER OF SEQUENCES: 210
       CORRESPONDENCE ADDRESS:
              ADDRESSEE: OLIFF & BERRIDGE, PLC
             STREET: P.O. BOX 19928
             CITY: ALEXANDRIA
;
             STATE: VA
             COUNTRY: USA
             ZIP: 22320
       COMPUTER READABLE FORM:
             MEDIUM TYPE: Floppy disk
              COMPUTER: IBM PC compatible
              OPERATING SYSTEM: PC-DOS/MS-DOS
              SOFTWARE: PatentIn Release #1.0, Version #1.30
   CURRENT APPLICATION DATA:
              APPLICATION NUMBER: US/08/979,847B
              FILING DATE: 26-No. 6582703-1997
              CLASSIFICATION:
       ATTORNEY/AGENT INFORMATION:
              NAME: BERRIDGE, WILLIAM P.
              REGISTRATION NUMBER: 30,024
              REFERENCE/DOCKET NUMBER: WPB 39046A
        TELECOMMUNICATION INFORMATION:
              TELEPHONE: 703-836-6400
              TELEFAX: 703-836-2787
  INFORMATION FOR SEO ID NO: 108:
   SEQUENCE CHARACTERISTICS:
             LENGTH: 1329 base pairs
              TYPE: nucleic acid
              STRANDEDNESS: single
```

```
TOPOLOGY: linear
          MOLECULE TYPE: cDNA
          SEQUENCE DESCRIPTION: SEO ID NO: 108:
US-08-979-847B-108
  Query Match
                              99.8%;
                                        Score 1326; DB 4; Length 1329;
  Best Local Similarity 100.0%; Pred. No. 0;
  Matches 1329; Conservative
                                     0; Mismatches
                                                            0; Indels
Gaps
         0;
           1 TCAAAATCGAAGAGCTTTAGACTTGCTAACCGCCAAAAGAGGGGGGAACCTGTTTATTTT 60
QУ
           1 TCAAAATCGAAGAGCTTTAGACTTGCTAACCGCCAAAAGAGGGGGGAACCTGTTTATTTT 60
Dh
          61 AGGGGAAGAATGCTGTTAGTATGTTAATCAATCTGGAATCATTACTGAGAAAGTTAAAGA 120
Db
          61 AGGGGAAGAATGCTGTTAGTATGTTAATCAATCTGGAATCATTACTGAGAAAGTTAAAGA 120
         121 AATTTGAGATCGAATATAATGTAGAGCAGAGGACCTTCAAAACACTGCACCCTGGGGCCT 180
Dh
         121 AATTTGAGATCGAATATAATGTAGAGCAGAGGACCTTCAAAACACTGCACCCTGGGGCCT 180
Qy
         181 CCTCAGCCAATGGATGCCCTGGACTCTCCCCTTCTTAGGACCTCTAGCAGCTATAATATT 240
         181 CCTCAGCCAATGGATGCCCTGGACTCTCCCCTTCTTAGGACCTCTAGCAGCTATAATATT 240
Dh
         241 TTTACTCCTCTTTGGACCCTGTATCTTCAACTTCCTTGTTAAGTTTGTCTCTTCCAGAAT 300
Db
         241 TTTACTCCTCTTTGGACCCTGTATCTTCAACTTCCTTGTTAAGTTTGTCTCTTCCAGAAT 300
         301 TGAAGCTGTAAAGCTACAAATAGTTCTTCAAATGGAACCCCAGATGCAGTCCATGACTAA 360
         301 TGAAGCTGTAAAGCTACAAATAGTTCTTCAAATGGAACCCCAGATGCAGTCCATGACTAA 360
Dh
         361 AATCTACCGTGGACCCCTGGACCGCCTGCTAGACTATGCTCTGATGTTAATGACATTGA 420
Dh
         361 AATCTACCGTGGACCCCTGGACCGCCTGCTAGACTATGCTCTGATGTTAATGACATTGA 420
         421 AGTCACCCCTCCCGAGGAAATCTCAACTGCACAACCCCTACTACACTCCAATTCAGTAGG 480
Dh
         421 AGTCACCCCTCCGAGGAAATCTCAACTGCACACCCCTACTACACTCCAATTCAGTAGG 480
Qy
         481 AAGCAGTTAGAGCAGTTGTCAGCCAACCTCCCCAACAGTACTTGGGTTTTCCTGTTGAGA 540
Dh
         481 AAGCAGTTAGAGCAGTTGTCAGCCAACCTCCCCAACAGTACTTGGGTTTTCCTGTTGAGA 540
         541 GGGTGGACTGAGAGACAGGACTAGCTGGATTTCCTAGGCTGACTAAGAATCCCNAAGCCT 600
Dh
         541 GGGTGGACTGAGACAGGACTAGCTGGATTTCCTAGGCTGACTAAGAATCCCNAAGCCT 600
         601 ANCTGGGAAGGTGACCGCATCCATCTTTAAACATGGGGCTTGCAACTTAGCTCACACCCG 660
         601 ANCTGGGAAGGTGACCGCATCCATCTTTAAACATGGGGCTTGCAACTTAGCTCACACCCG 660
Db
         661 ACCANTCAGAGAGCTCACTAAAATGCTAATCAGGCAAAAACAGGAGGTAAAGCAATAGCC 720
Dh
         661 ACCAATCAGAGAGCTCACTAAAATGCTAATCAGGCAAAAACAGGAGGTAAAGCAATAGCC 720
```

Qy	721	AATCATCTATTGCCTGAGAGCACAGCGGGAAGGACAAGGATTGGGATATAAACTCAGGCA	780
Db	721	${\tt AATCATCTATTGCCTGAGAGCACAGCGGGAAGGACAAGGATTGGGATATAAACTCAGGCA}$	780
Qy	781	TTCAAGCCAGCAACAGCAACCCCTTTGGGTCCCCTCCCATTGTATGGGAGCTCTGTTTT	840
Db	781	$\tt TTCAAGCCAGCAACAGCAACCCCCTTTGGGTCCCCTCCCATTGTATGGGAGCTCTGTTTT$	840
Qy	841	${\tt CACTCTATTCACTCTATTAAATCATGCAACTGCACTCTTCTGGTCCGTGTTTTTTATGG}$	900
Db	841	CACTCTATTCACTCTATTAAATCATGCAACTGCACTCTTCTGGTCCGTGTTTTTTATGG	900
Qy	901	$\tt CTCAAGCTGAGCTTTTGTTCGCCATCCACCACTGCTGTTTGCCACCGTCACAGACCCGCT$	960
Db	901	CTCAAGCTGAGCTTTGTTCGCCATCCACCACTGCTGTTTGCCACCGTCACAGACCCGCT	960
QУ	961	$\tt GCTGACTTCCATCCCTTTGGATCCAGCAGAGTGTCCACTGTGCTCCTGATCCAGCGAGGT$	1020
Db	961	GCTGACTTCCATCCCTTTGGATCCAGCAGAGTGTCCACTGTGCTCCTGATCCAGCGAGGT	1020
Qy	1021	${\tt ACCCATTGCCACTCCCGATCAGGCTAAAGGCTTGCCATTGTTCCTGCATGGCTAAGTGCC}$	1080
Db	1021	ACCCATTGCCACTCCGATCAGGCTAAAGGCTTGCCATTGTTCCTGCATGGCTAAGTGCC	1080
Qy	1081	$\tt TGGGTTTGTCCTAATAGAACTGAACACTGGTCACTGGTTCCATGGTTCTCTTCCATGAC$	1140
Db	1081	TGGGTTTGTCCTAATAGAACTGAACACTGGTCACTGGTTCCATGGTTCTCCATGAC	1140
QУ	1141	$\tt CCACGGCTTCTAATAGAGCTATAACACTCACCGCATGGCCCAAGATTCCATTCCTTGGTA$	1200
Db	1141	CCACGGCTTCTAATAGAGCTATAACACTCACCGCATGGCCCAAGATTCCATTCCTTGGTA	1200
Qy	1201	${\tt TCTGTGAGGCCAAGAACCCCAGGTCAGAGAANGTGAGGCTTGCCACCATTTGGGAAGTGG}$	1260
Db	1201	TCTGTGAGGCCAAGAACCCCAGGTCAGAGAANGTGAGGCTTGCCACCATTTGGGAAGTGG	1260
QУ	1261	$\tt CCCACTGCCATTTTGGTAGCGGCCCACCACCATCTTGGGAGCTGTGGGAGCAAGGATCCC$	1320
Db	1261	CCCACTGCCATTTGGTAGCGGCCCACCACCTCTGGGAGCTGTGGGAGCAAGGATCCC	1320
Qy	1321	CCAGTAACA 1329	
Db	1321	CCAGTAACA 1329	